Sheridan John F 4

What Happened

• John F. Sheridan, President & CEO of Tandem Diabetes Care (TNDM), had RSUs convert to common stock on 2026-02-17. The filing shows the conversion/acquisition of 11,454 shares (5,471 + 5,983) from vested RSUs and the company withheld 4,363 shares to satisfy tax withholding obligations at $18.95 per share (total withheld value reported as $37,199 and $45,480, combined ~$82,679). Net shares delivered to Sheridan after withholding: 7,091.

Key Details

• Transaction date: 2026-02-17; filing date: 2026-02-19 (filed timely).
• Reported entries: M = conversion/exercise of derivative (RSU) into 11,454 shares; F = shares withheld for taxes (4,363 shares) at $18.95.
• Cash value of shares withheld: $37,199 (1,963 shares) + $45,480 (2,400 shares) = $82,679.
• Shares owned after the transaction: not specified in the Form 4.
• Footnotes: F1 notes shares were withheld by the company to satisfy tax withholding (no open‑market sale). F2–F6 describe the awards under the 2023 Long‑Term Incentive Plan and the RSU vesting schedules; F3 notes RSUs may be settled in stock or cash at the company’s discretion.

Context

• This was vesting/settlement of RSUs, not an open‑market purchase or sale. The company withheld shares to cover taxes (a routine cashless-withholding settlement), so no shares were sold on the market. The filing uses code M (derivative exercise/convert) for the RSU settlement and code F for tax-withholding.